DUSA Pharmaceuticals (DUSA)
DUSA Pharmaceuticals Long Term Debt: 0.00
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
DUSA Long Term Debt Rankings
| Overall | 99th percentile | 1 of 4657 |
| Sector | 99th percentile | 1 of 525 in Healthcare |
| Industry | 97th percentile | 1 of 42 in Drug Manufacturers - Other |
DUSA Long Term Debt Range, Past 5 Years
| Minimum | 0.00 | Jun 2007 |
| Maximum | 0.00 | Jun 2007 |
| Average | 0.00 |
About Long Term Debt
Long-term debts are financial obligations and loans lasting longer than one year. A company must report long-term debt on its balance sheet with its date of maturity and interest rate.
Bonds and debt obligations with maturities greater than one year are examples of long-term debt. Other types of securities, including short-term notes and commercial papers usually are not long-term debt because their maturities typically are shorter than one year.
Learn More
You may also be interested in these DUSA related companies
DUSA News
$DUSA - Initial Stop hit. Trade close @ Initial Stop of $5.10 - http://stks.co/3so5
about 12 days ago by TraderFoxxx
about 12 days ago by TraderFoxxx
$DUSA forms bearish "Diamond Top" chart pattern. http://stks.co/3mUY
about 18 days ago by RecogniaEvents
about 18 days ago by RecogniaEvents
Listen to $DUSA Q1 2012 earnings call - live at 08:30 AM, ondemand after - http://stks.co/3iR7
about 21 days ago by earningscast
about 21 days ago by earningscast
DUSA Pharmaceuticals Reports First Quarter 2012 Corporate Highlights and Financial Results
May 08, 6:30AM GlobeNewswire
May 08, 6:30AM GlobeNewswire
DUSA Pharmaceuticals Completes Enrollment in Phase 2 Studies of Levulan(R) Kerastick(R) Photodynamic Therapy
Apr 24, 7:30AM GlobeNewswire
Apr 24, 7:30AM GlobeNewswire
DUSA Pharmaceuticals Introduces Teeing Off Against Sun Damage(TM) Campaign to Raise Awareness of Actinic Keratosis
Apr 10, 8:30AM GlobeNewswire
Apr 10, 8:30AM GlobeNewswire
Trade Signal-New $DUSA -BTO @ 6.48-Limit w/5.10-Stop on the Wkly Chart w/.5N @ Risk http://chart.ly/t5llhwx
about 64 days ago by TraderFoxxx
about 64 days ago by TraderFoxxx
DUSA Pharmaceuticals to Present at the 2012 Maxim Group Growth Conference
Mar 23, 8:00AM GlobeNewswire
Mar 23, 8:00AM GlobeNewswire
$DUSA http://stks.co/2wc5 broke over lower range on volume of 150% of full day average - has a level overhead
about 71 days ago by StockTiger
about 71 days ago by StockTiger
DUSA Pharmaceuticals to Present at the 2012 Maxim Group Growth Conference
Mar 19, 8:30AM GlobeNewswire
Mar 19, 8:30AM GlobeNewswire
DUSA Pharmaceuticals to Present at Roth Capital Partners 24th Annual OC Growth Stock Conference
Mar 07, 8:30AM GlobeNewswire
Mar 07, 8:30AM GlobeNewswire
Listen to $DUSA Q4 2011 earnings call - live at 08:30 AM, ondemand after - http://stks.co/2giF
about 84 days ago by earningscast
about 84 days ago by earningscast
DUSA Pharmaceuticals Reports Full Year 2011 Corporate Highlights and Financial Results
Mar 06, 6:30AM GlobeNewswire
Mar 06, 6:30AM GlobeNewswire
DUSA Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference
Feb 08, 8:30AM GlobeNewswire
Feb 08, 8:30AM GlobeNewswire
DUSA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference
Feb 06, 9:10AM GlobeNewswire
Feb 06, 9:10AM GlobeNewswire
DUSA Pharmaceuticals, Inc. (DUSA) CEO to Ring The NASDAQ Stock Market Opening Bell
Dec 21, 12:20PM GlobeNewswire
Dec 21, 12:20PM GlobeNewswire
DUSA Pharmaceuticals Reports Third Quarter 2011 Corporate Highlights and Financial Results
Nov 10, 6:30AM GlobeNewswire
Nov 10, 6:30AM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| DUSA | 5.44 | +0.04 | +0.74% | 134.10M |
| DUK | 21.96 | +0.16 | +0.73% | 29.38B |
| DUG | 27.46 | +0.20 | +0.73% | |
| DUF | 14.83 | -0.07 | -0.47% | 515.79M |
| DUCK | 8.11 | +0.09 | +1.12% | 31.14M |
| DUC | 12.40 | +0.06 | +0.49% | |
| DTV | 46.40 | +0.03 | +0.06% | 31.39B |
| DRH | 9.85 | -0.01 | -0.10% | 1.661B |
| DRE | 13.72 | -0.07 | -0.51% | 3.569B |
| DRD | 6.24 | +0.06 | +0.97% | 240.18M |
